Osteogenesis Imperfecta (OI) is a genetic condition causing fragile bones, often leading to fractures. This study compares two treatments: romosozumab (a medication that helps bones get stronger) and bisphosphonates (a common treatment for weak bones). The study lasts 12 months and aims to see which treatment is better at preventing fractures and improving bone strength.

Key Points:

• The study lasts for 12 months, with regular check-ups.
• Participants are children aged 5-17 with OI.
• Participation includes medical assessments and possibly some risks.

To join, children must have had multiple fractures in the past two years and meet other health criteria. Some exclusions apply, like having certain genetic patterns or medical histories. A parent or guardian must consent if the child is too young. The goal is to find the safest and most effective treatment for improving bone health in children with OI.